⌘K
t
Polarean Imaging Plc announced that as of 28 July 2022, its total voting rights and shares in issue amounted to 213,047,509 ordinary shares of £0.00037 each. The company also provided a Block Listing Return for its Polarean Share Option Plan, reporting that 3,531,313 securities were issued under the scheme between 28 January 2022 and 27 July 2022, leaving 4,025,657 unallotted securities.
| Date | 28 Jul 2022 |
| Time | 07:00:06 |
| Category | Capital structure |
| ID | 9754T |
Polarean Imaging Plc
("Polarean" or the "Company")
Total voting rights and Block Listing Return
Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product using hyperpolarised xenon-129 gas to enhance magnetic resonance imaging (MRI) in pulmonary medicine, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 213,047,509 ordinary shares of £0.00037 each ("Ordinary Shares").
The total issued share capital of the Company consists of 213,047,509 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
|
Name of applicant: |
Polarean Imaging Plc |
|||
|
Name of scheme: |
Polarean Share Option Plan |
|||
|
Number and class of securities originally admitted: |
8,000,000 ordinary shares of £0.00037 each |
|||
|
Date of admission: |
29 July 2021 |
|||
|
Period of return: |
From: |
28 January 2022 |
To: |
27 July 2022 |
|
Balance of unallotted securities under scheme(s) from previous return: |
7,556,970 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
0 |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
3,531,313
|
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
4,025,657 |
|||
|
Total number of securities in issue at the end of the period |
213,047,509 |
|||
|
Name of contact: |
Richard Hullihen, Chief Executive Officer |
|
Telephone number of contact: |
+44 (0)20 7933 8780 or [email protected] |
Enquiries:
|
Polarean Imaging plc |
|||||
|
Richard Hullihen, Chief Executive Officer |
Via Walbrook PR |
||||
|
Kenneth West, Chairman |
|
||||
|
|
|
||||
|
Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) |
+44 (0)20 7710 7600 |
||||
|
Nicholas Moore / Samira Essebiyea / William Palmer-Brown (Healthcare Investment Banking) |
|
||||
|
Nick Adams / Fred Walsh / Nick Harland (Corporate Broking) |
|||||
|
|
|
||||
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or [email protected] |
||||
|
Anna Dunphy /Phillip Marriage |
Mob: +44 (0)7879 741 001 / +44 (0) 7867 984 082 |
||||
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation. 129Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream.
In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA for hyperpolarised 129Xe used to evaluate pulmonary function and to visualise the lung using MRI. The Group received a complete response letter on 5 October 2021. On 30 March 2022, the Company filed the resubmission of its NDA with the US FDA and has received a PDUFA date of Sept 30, 2022.
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform.